CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides

Objective. The Canadian Vasculitis research network (CanVasc) is composed of physicians from different medical specialties and researchers with expertise in vasculitis. One of its aims is to develop recommendations for the diagnosis and management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada. Methods. Diagnostic and therapeutic questions were developed based on the results of a national needs assessment survey. A systematic review of existing non-Canadian recommendations and guidelines for the diagnosis and management of AAV and studies of AAV published after the 2009 European League Against Rheumatism/European Vasculitis Society recommendations (publication date: January 2009) until November 2014 was performed in the Medline database, Cochrane library, and main vasculitis conference proceedings. Quality of supporting evidence for each therapeutic recommendation was graded. The full working group as well as additional reviewers, including patients, reviewed the developed therapeutic recommendations and nontherapeutic statements using a modified 2-step Delphi technique and through discussion to reach consensus. Results. Nineteen recommendations and 17 statements addressing general AAV diagnosis and management were developed, as well as appendices for practical use, for rheumatologists, nephrologists, respirologists, general internists, and all other healthcare professionals more occasionally involved in the management of patients with AAV in community and academic practice settings. Conclusion. These recommendations were developed based on a synthesis of existing international guidelines, other published supporting evidence, and expert consensus considering the Canadian healthcare context, with the intention of promoting best practices and improving healthcare delivery for patients with AAV.

[1]  Rohit Sharma.  Revised International Chapel Hill Consensus Conference nomenclature of vasculitides , 2016, Radiopaedia.org.

[2]  A. Webster,et al.  Interventions for renal vasculitis in adults , 2016, Nephrology.

[3]  C. Pineau,et al.  Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire , 2015, The open rheumatology journal.

[4]  P. Ravaud,et al.  Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy , 2015, Arthritis & rheumatology.

[5]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[6]  G. Hoffman,et al.  Rituximab With or Without a Conventional Maintenance Agent in the Treatment of Relapsing Granulomatosis With Polyangiitis (Wegener's): A Retrospective Single‐Center Study , 2014, Arthritis & rheumatology.

[7]  L. Mouthon,et al.  Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. , 2014, Autoimmunity reviews.

[8]  F. Moosig,et al.  Current and emerging techniques for ANCA detection in vasculitis , 2014, Nature Reviews Rheumatology.

[9]  B. Iung,et al.  Prevalence of Antineutrophil Cytoplasmic Antibodies in Infective Endocarditis , 2014 .

[10]  A. Humar,et al.  Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of glomerulonephritis in adults. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  O. Decaux,et al.  Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. , 2014, Rheumatology.

[12]  D. Jayne,et al.  Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis , 2014, Current opinion in rheumatology.

[13]  J. Krischer,et al.  An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's) , 2013, Annals of the rheumatic diseases.

[14]  G. Hoffman,et al.  Granulomatosis With Polyangiitis (Wegener’s) , 2014, Medicine.

[15]  K. Chakravarty,et al.  BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. , 2014, Rheumatology.

[16]  S. Stewart,et al.  Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada? , 2013, Rheumatology.

[17]  B. Bonnotte,et al.  Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. , 2013, Presse medicale.

[18]  P. Merkel,et al.  Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. , 2013, Arthritis and rheumatism.

[19]  P. Merkel,et al.  ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS) , 2013, Clinical and Experimental Nephrology.

[20]  P. Höglund,et al.  Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. , 2013, Kidney international.

[21]  C. Pieper,et al.  Pregnancy Outcomes Among Patients With Vasculitis , 2013, Arthritis care & research.

[22]  P. Merkel,et al.  Efficacy of remission-induction regimens for ANCA-associated vasculitis. , 2013, The New England journal of medicine.

[23]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[24]  P. Conaghan,et al.  Safety evaluation of leflunomide in rheumatoid arthritis , 2013, Expert opinion on drug safety.

[25]  W. Koldingsnes,et al.  Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. , 2013, Rheumatology.

[26]  P. Merkel,et al.  Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial , 2013, Trials.

[27]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[28]  L. Mouthon,et al.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. , 2013, Arthritis and rheumatism.

[29]  B. Landis,et al.  Diagnostic Value of Biopsies in Identifying Cytoplasmic Antineutrophil Cytoplasmic Antibody–negative Localized Wegener's Granulomatosis Presenting Primarily with Sinonasal Disease , 2012, American journal of rhinology & allergy.

[30]  Kenneth G. C. Smith,et al.  Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[31]  T. Peikert,et al.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. , 2012, Arthritis and rheumatism.

[32]  P. Höglund,et al.  Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[33]  C. Bombardier,et al.  Emerging Issues in Pharmacological Management of Rheumatoid Arthritis: Results of a National Needs Assessment Survey Identifying Practice Variations for the Development of Canadian Rheumatology Association Clinical Practice Recommendations , 2012, Journal of Rheumatology.

[34]  C. Bombardier,et al.  Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety , 2012, The Journal of Rheumatology.

[35]  C. Bombardier,et al.  Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs , 2012, The Journal of Rheumatology.

[36]  Jai Radhakrishnan,et al.  Notice , 2012, Kidney International Supplements.

[37]  A. Reiff,et al.  Assessing the Performance of the Birmingham Vasculitis Activity Score at Diagnosis for Children with Antineutrophil Cytoplasmic Antibody-associated Vasculitis in A Registry for Childhood Vasculitis (ARChiVe) , 2012, The Journal of Rheumatology.

[38]  C. Stegeman,et al.  Pregnancy in women diagnosed with Antineutrophil cytoplasmic antibody–associated vasculitis: Outcome for the mother and the child , 2012, Arthritis care & research.

[39]  I. Bruce,et al.  Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. , 2012, Rheumatology.

[40]  C. Pagnoux,et al.  Vasculitis of the upper airways. , 2012, Swiss medical weekly.

[41]  P. Höglund,et al.  Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[42]  Yichun Hu,et al.  Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[43]  L. Mouthon,et al.  Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis , 2012, The Journal of Rheumatology.

[44]  V. Tesar,et al.  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up , 2011, Annals of the rheumatic diseases.

[45]  P. Merkel,et al.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. , 2012, Rheumatology.

[46]  F. Moosig,et al.  Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. , 2012, Clinical and experimental rheumatology.

[47]  R. Geenen,et al.  Patient and spouse appraisals of health status in rheumatoid arthritis and fibromyalgia: discrepancies and associations with invalidation. , 2011, Clinical and experimental rheumatology.

[48]  N. Milman,et al.  Cutaneous vasculopathy associated with cocaine use , 2011, Arthritis care & research.

[49]  D. Schroeder,et al.  Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. , 2011, Arthritis and rheumatism.

[50]  E. McCloskey,et al.  FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[51]  D. Jayne,et al.  Management of alveolar hemorrhage in lung vasculitides. , 2011, Seminars in respiratory and critical care medicine.

[52]  R. Dhôte,et al.  Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. , 2011, Arthritis and rheumatism.

[53]  L. Mouthon,et al.  Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. , 2011, Rheumatology.

[54]  P. Merkel,et al.  Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[55]  P. Merkel,et al.  A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis , 2011, Arthritis care & research.

[56]  L. Mouthon,et al.  The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.

[57]  R. Franco.  Intralesional Corticosteroid Injection and Dilatation Provides Effective Management of Subglottic Stenosis in Wegener's Granulomatosis , 2011 .

[58]  Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[59]  L. Mouthon,et al.  Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. , 2011, Clinical and experimental rheumatology.

[60]  I. Witterick,et al.  Intralesional corticosteroid injection and dilatation provides effective management of subglottic stenosis in Wegener's granulomatosis , 2010, The Laryngoscope.

[61]  V. Tesar,et al.  Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. , 2010, JAMA.

[62]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[63]  J. Pouchot,et al.  Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. , 2010, Rheumatology.

[64]  E. Harvey,et al.  Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis , 2010, Arthritis care & research.

[65]  P. Merkel,et al.  Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysis , 2010, Arthritis care & research.

[66]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[67]  P. van Paassen,et al.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. , 2010, The New England journal of medicine.

[68]  E. Israel,et al.  Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.

[69]  A. Bakkaloğlu,et al.  EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria , 2010, Annals of the rheumatic diseases.

[70]  C. Ribi,et al.  Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. , 2010, Arthritis and rheumatism.

[71]  P. Lamprecht,et al.  Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis , 2010, Current opinion in rheumatology.

[72]  P. Seo.  Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis , 2010 .

[73]  P. Merkel,et al.  Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. , 2010, Arthritis and rheumatism.

[74]  W. Lukas,et al.  Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement , 2009, European journal of medical research.

[75]  L. Jacobsson,et al.  Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.

[76]  A. Reiff,et al.  Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. , 2009, Arthritis and rheumatism.

[77]  Kenneth G. C. Smith,et al.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2009, Arthritis and rheumatism.

[78]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[79]  H. Raspe,et al.  EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.

[80]  K. Bassett,et al.  Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. , 2009, The Cochrane database of systematic reviews.

[81]  L. Mouthon,et al.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.

[82]  E. Pallisa,et al.  Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis , 2008, Lupus.

[83]  L. Guillevin,et al.  Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. , 2008, Arthritis and rheumatism.

[84]  N. Toussaint,et al.  Induction and maintenance therapy in ANCA‐associated systemic vasculitis , 2008, Nephrology.

[85]  G. Luxton,et al.  ANCA serology in the diagnosis and management of ANCA‐associated renal vasculitis , 2008, Nephrology.

[86]  J. Stone,et al.  When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. , 2008, Arthritis and rheumatism.

[87]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[88]  C. Ribi,et al.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. , 2008, Arthritis and rheumatism.

[89]  L. Guillevin,et al.  Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients , 2007, Annals of the rheumatic diseases.

[90]  A. Chaudhry,et al.  Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H) , 2007, Annals of the rheumatic diseases.

[91]  H. Raspe,et al.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.

[92]  A. Loft,et al.  Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. , 2008, The Journal of rheumatology.

[93]  L. Mouthon,et al.  Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. , 2008, Arthritis and rheumatism.

[94]  L. Leibovici,et al.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. , 2014, The Cochrane database of systematic reviews.

[95]  M. Kimura,et al.  Comparison of trimethoprim–sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease , 2008, Rheumatology International.

[96]  K. Chakravarty,et al.  BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. , 2007, Rheumatology.

[97]  L. Jacobsson,et al.  Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. , 2007, Rheumatology.

[98]  Augustine S. Lee,et al.  ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. , 2007, The American journal of medicine.

[99]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[100]  K. De Groot,et al.  Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. , 2007, Rheumatology.

[101]  P. Seo.  Pregnancy and vasculitis. , 2007, Rheumatic diseases clinics of North America.

[102]  H. Raspe,et al.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.

[103]  T. Therneau,et al.  How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? , 2005, Arthritis and rheumatism.

[104]  C. Feighery,et al.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[105]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[106]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .

[107]  B. Thiers.  Etanercept plus standard therapy for Wegener's granulomatosis. , 2005, The New England journal of medicine.

[108]  Augustine S. Lee,et al.  Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. , 2004, Arthritis and rheumatism.

[109]  F Guillemin,et al.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.

[110]  C. Langford,et al.  Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. , 2004, Arthritis and rheumatism.

[111]  P. Bacon,et al.  Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. , 2004, Journal of the American Society of Nephrology : JASN.

[112]  D. Henke,et al.  Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[113]  J. Stone.  Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. , 2003, Arthritis and rheumatism.

[114]  J. Kasperbauer,et al.  Subglottic Stenosis Associated With Wegener's Granulomatosis , 2003, The Laryngoscope.

[115]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[116]  C. Langford,et al.  Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. , 2003, The American journal of medicine.

[117]  D. Jayne,et al.  Safety and efficacy of TNFα blockade in relapsing vasculitis , 2002 .

[118]  C. Langford,et al.  Pregnancy in vasculitis , 2002, Current opinion in rheumatology.

[119]  D. Jayne,et al.  Safety and efficacy of TNFalpha blockade in relapsing vasculitis. , 2002, Annals of the rheumatic diseases.

[120]  A. Gibofsky.  American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[121]  D. Adu,et al.  The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[122]  G A Colditz,et al.  Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. , 2001, The Journal of rheumatology.

[123]  L. Guillevin,et al.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. , 2001, Arthritis and rheumatism.

[124]  P. Limburg,et al.  Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. , 2000, Arthritis and rheumatism.

[125]  D. Adu,et al.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.

[126]  J. Stone,et al.  Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. , 1999, The Journal of rheumatology.

[127]  S. James,et al.  Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease: Part 2: Inflammatory Bowel Disease, Systemic Vasculitis, and Therapeutic Toxicity , 1998, Annals of Internal Medicine.

[128]  P Lesavre,et al.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. , 1998, Kidney international.

[129]  B. Hoen,et al.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. , 1997, Arthritis and rheumatism.

[130]  D. Adu,et al.  Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. , 1997, QJM : monthly journal of the Association of Physicians.

[131]  C. Kallenberg,et al.  Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[132]  P. D. de Jong,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. , 1996, The New England journal of medicine.

[133]  C. Kallenberg,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .

[134]  M. Heller,et al.  Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. , 1996, QJM : monthly journal of the Association of Physicians.

[135]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[136]  J. Piette,et al.  Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. , 1995, Annals of the rheumatic diseases.

[137]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[138]  E. Hachulla,et al.  Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. , 1993, Clinical and experimental rheumatology.

[139]  W. Travis,et al.  The management of subglottic stenosis in patients with wegener's granulomatosis , 1992, The Laryngoscope.

[140]  Guy Hoffman,et al.  The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. , 1992, Arthritis and rheumatism.

[141]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[142]  M. Davies,et al.  Treatment of systemic vasculitis with pooled intravenous immunoglobulin , 1991, The Lancet.

[143]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. , 2010, Arthritis and rheumatism.

[144]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[145]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.